MedTrace Logo

Comparing IVF/ICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol With Elonva Without GnRH Antagonist to Follicular Phase Day 2 Stimulation Fixed Day 5 Antagonist Protocol

NCT06879002 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 252

Last updated 2026-05-07

No results posted yet for this study

Summary

There are several approaches to the timing of antagonist administration in IVF/ICSI cycles. The primary goal is indeed to prevent premature ovulation, which could jeopardize the success of the cycle There is an emerging concept that suggests that the progesterone produced by the corpus luteum (formed after ovulation) might be sufficient to prevent further ovulation, obviating the need for antagonist or exogenous progesterone administration. This hypothesis relies on the natural regulatory mechanisms of the menstrual cycle to maintain a progesterone-dominated environment post-ovulation. We hypothesized that this approach would minimize treatment costs /burden without having an impact on the outcome.

Conditions

  • Stimulation in the Ovary
  • IVF Outcome

Interventions

OTHER

Ovarian stimulation with menstruation or after ovulation

Ovarian stimulation with menstruation or after ovulation

Sponsors & Collaborators

  • ART Fertility Clinics LLC

    lead OTHER

Principal Investigators

  • Barbara Lawrenz, PhD · ART Fertility Clinics LLC

Eligibility

Min Age
18 Years
Max Age
38 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-12-30
Primary Completion
2027-04-30
Completion
2027-12-30

Countries

  • United Arab Emirates

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06879002 on ClinicalTrials.gov